These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 22136812)

  • 1. From evidence assessments to coverage decisions?: the case example of glinides in Germany.
    Kreis J; Busse R
    Health Policy; 2012 Jan; 104(1):27-31. PubMed ID: 22136812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Closing evidence gaps].
    Lange S
    Z Evid Fortbild Qual Gesundhwes; 2011; 105(9):652-6. PubMed ID: 22152422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Questioning patient subgroups for benefit assessment: challenging the German Gemeinsamer Bundesausschuss approach.
    Ruof J; Dintsios CM; Schwartz FW
    Value Health; 2014 Jun; 17(4):307-9. PubMed ID: 24968988
    [No Abstract]   [Full Text] [Related]  

  • 6. Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy.
    Müller T
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():1-3. PubMed ID: 18987904
    [No Abstract]   [Full Text] [Related]  

  • 7. [Cost-effectiveness evaluation of drugs: multidisciplinary collaboration and transparency are key].
    Mueller EA; Kirch W
    Med Klin (Munich); 2008 Oct; 103(10):712-6. PubMed ID: 18936896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [10 years of assessing prevention and early diagnosis programmes by the Federal Joint Committee of Germany - a methodological analysis].
    Bertelsmann H; Perleth M; Matthias K
    Gesundheitswesen; 2013 Jan; 75(1):7-12. PubMed ID: 22836934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Decision-analytical modelling of costs per QALY in the context of the German Social Law].
    Rogowski WH; Landauer M; John J
    Gesundheitswesen; 2009 Nov; 71(11):739-50. PubMed ID: 19551622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Comments by the Working Group for Methods of Economic Evaluation in Health Care (AG MEG) to IQWiG's Draft Guidelines "Methods for Assessment of the Relation of Benefits to Costs in the German Statutory Health Care System"].
    Krauth C; John J; Aidelsburger P; Brüggenjürgen B; Hansmeier T; Hessel F; Kohlmann T; Moock J; Rothgang H; Schweikert B; Seitz R; Wasem J;
    Gesundheitswesen; 2008 Jun; 70(6):e1-16. PubMed ID: 18661452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biostatistical aspects for the use of evidence based medicine in health technology assessment.
    Freemantle N
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():31-43. PubMed ID: 18987906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A short history of health technology assessment in Germany.
    Perleth M; Gibis B; Göhlen B
    Int J Technol Assess Health Care; 2009 Jul; 25 Suppl 1():112-9. PubMed ID: 19500440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knowledge-based changes to health systems: the Thai experience in policy development.
    Tangcharoensathien V; Wibulpholprasert S; Nitayaramphong S
    Bull World Health Organ; 2004 Oct; 82(10):750-6. PubMed ID: 15643796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Institute for Quality and Efficiency in Health Care: Germany.
    Nasser M; Sawicki P
    Issue Brief (Commonw Fund); 2009 Jul; 57():1-12. PubMed ID: 19639711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Key points of reform of the German health service 2003+. From the viewpoint of the Society of Private Practice Accounting Services].
    Urologe A; 2003 Jan; 42(1):136-8. PubMed ID: 14655650
    [No Abstract]   [Full Text] [Related]  

  • 17. [New, expensive antidiabetics for the treatment of type-2 diabetes--pro].
    Müller-Wieland D
    Dtsch Med Wochenschr; 2010 May; 135(18):922. PubMed ID: 20425678
    [No Abstract]   [Full Text] [Related]  

  • 18. [Experiences with and impact of health technology assessment on the German Standing Committee of physicians and patients].
    Gibis B; Rheinberger P
    Z Arztl Fortbild Qualitatssich; 2002 Feb; 96(2):82-90. PubMed ID: 11921610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Costs of the treatment of hyperglycemia in patients with diabetes mellitus. The impact of age, type of therapy and complications: results of the German CoDiM study].
    von Ferber L; Köster I; Hauner H
    Med Klin (Munich); 2006 May; 101(5):384-93. PubMed ID: 16685485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of technology assessment in health benefits coverage for medical devices.
    Braslow NM; Shatin D; McCarthy DB; Newcomer LN
    Am J Manag Care; 1998 Sep; 4 Spec No():SP139-50. PubMed ID: 10185990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.